Vilket är priset för Syntara Limited (SNT)

Priset för Syntara Limited (SNT) är $0.0183374

Vilket är marknadsvärdet för Syntara Limited (SNT)

Marknadsvärdet för Syntara Limited (SNT) är $27.51M

Syntara Limited (SNT) P/B-tal

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.

År	P/B-tal	Ändra
Inte tillräckligt med data för de angivna datumen.

År

P/B-tal

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	P/B-tal	Skillnad i P/B-tal	Land
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	5.5207	-	IN

Företag

P/B-tal

Skillnad i P/B-tal

Land